True Histiocytic Lymphoma Following Therapy for Lymphoblastic Neoplasms

By Robert A. Soslow, R. Eric Davis, Roger A. Warnke, Michael L. Cleary, and Onsi W. Kamel

True histiocytic lymphomas (THLs) are rare tumors in which the malignant cells show morphologic and immunophenotypic evidence of histiocytic differentiation. We describe THLs that arose after therapy for one case of T-lineage lymphoblastic lymphoma (LyL) and two cases of acute lymphoblastic leukemia (ALL) (both CD10+, one pre-B phenotype). The lymphoblastic neoplasms were not unusual in any way, and responded well to standard therapy. The THLs arose to 20 months after complete remission was achieved for the lymphoblastic neoplasms, at which time there was still no clinical or pathologic evidence of the lymphoblastic neoplasms. All three THLs exhibited clinical and morphologic features of malignancy. Neoplastic cells in the THLs had abundant eosinophilic vacuolated cytoplasm and pleomorphic nuclei, and expressed histiocytic antigens in the absence of lymphocyte-specific lineage markers. Because THLs are rare neoplasms, their occurrence after otherwise successful therapy for lymphoblastic neoplasms in these three cases may constitute a distinct clinicopathologic entity.

© 1996 by The American Society of Hematology.

From the Department of Pathology, Stanford University Medical Center, Stanford, CA.
Submitted July 7, 1995; accepted February 6, 1996.
Supported in part by Grants No. 34233 and 33119 from the National Cancer Institute and by a Stanford University Research Incentive Fund Award.
Address reprint requests to Onsi W. Kamel, MD, Department of Pathology, Stanford University Medical Center, 300 Pasteur Dr, Stanford, CA 94305.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1996 by The American Society of Hematology.

0006-4971/96/8712-0012$3.00/0


5207
Table 1. Immunophenotypic Results in Original Lymphoblastic Neoplasms and Subsequent THLs

<table>
<thead>
<tr>
<th>Case no. 1</th>
<th>LyL</th>
<th>THL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive: CD 3, 43, 45RO, and 45; TdT</td>
<td>Positive: CD 4, 11c, 13, 14, and 68</td>
<td>Positive: CD 4, 15, 30, 34, 45RA, and 45RO: lysozyme</td>
</tr>
<tr>
<td>Negative: CD 20, 34, and 68; myeloperoxidase</td>
<td>Negative: CD 1a, 3, 5, 7, 8, 19, and 30</td>
<td>Negative: CD 1, 2, 3, 4, 5, 7, 8, 13, and 33; T-cell receptor beta and delta chains</td>
</tr>
<tr>
<td>Case no. 2</td>
<td>ALL</td>
<td>THL</td>
</tr>
<tr>
<td>Positive: CD 10, 19, 22 (surface), and 34; IgM (cytoplasmic); TdT; HLA-DR</td>
<td>Positive: CD 45 and 68; S100 protein (in scattered cells)</td>
<td>Positive: CD 1, 2, 3, 4, 5, and 22 (surface)</td>
</tr>
<tr>
<td>Case no. 3</td>
<td>ALL</td>
<td>THL</td>
</tr>
<tr>
<td>Positive: CD10</td>
<td>Positive: CD68, S100 protein (focal staining)</td>
<td>Positive: CD 3, 15, 20, 30, 34, 45RA, and 45RO: lysozyme</td>
</tr>
<tr>
<td>Negative: not specified</td>
<td>Negative: CD 15, 20, 30, 34, 45RA, and 45RO; S100 protein</td>
<td>Negative: CD 1, 2, 3, 4, 5, and 22 (surface)</td>
</tr>
</tbody>
</table>

Abbreviation: TdT, terminal deoxynucleotidyl transferase.

The three THLs were morphologically distinct from the original lymphoblastic neoplasms. The THLs were composed of large pale-staining cells that were loosely cohesive to noncohesive, and contained abundant vacuolated pink cytoplasm. The nuclei ranged from round to oval to bean-shaped and demonstrated a vesicular chromatin pattern. Multinucleated tumor giant cells were present in each case, as were cytologic features of pleomorphism or frank anaplasia (Fig 1B). In some areas in case no. 3, the constituent cells showed a more uniform appearance, with nuclei containing grooves or folds suggestive of Langerhans cell differentiation (Fig 2); however, the other areas of the tumor showed morphologic features (described earlier) that precluded this diagnosis. Mitotic figures were a consistent finding. Hemophagocytosis was present, but was not prominent. Other morphologic features included areas of tumor-cell necrosis and focal collections of neutrophils. There was no evidence of residual lymphoblastic neoplasmia in any of the three cases.

As summarized in Table 1, the THLs stained with one or more histiocytic markers, including CD11c, CD13, CD14, or CD68 (Fig 2B). Individual cases also demonstrated immunoreactivity with CD45, cytoplasmic CD4, and S100 (scattered positive cells in case no. 2 and focal S100 staining in case no. 3), markers that may be seen in cells of histiocytic lineage. In contrast, tumor cells showed no reactivity with markers specific for B or T lineages, or for CD30.

In situ hybridization for EBV. All three cases were negative for EBV EBER-1 RNA. The integrity of mRNA in the

Abbreviation: TdT, terminal deoxynucleotidyl transferase.

From www.bloodjournal.org by guest on October 3, 2017. For personal use only.
TRUE HISTIOCYTIC LYMPHOMAS

Fig 1. The LyL (A, hematoxylin and eosin) and the THL (B, hematoxylin and eosin) that developed 15 months following a successful bone marrow transplantation in patient no. 1. The THL showed a clonal rearrangement of the TCR-beta gene. Original magnifications × 600.

Fig 2. The THL in patient no. 3 showed cells with nuclear pleomorphism (A, hematoxylin and eosin; original magnification × 400) and also showed some areas containing cells with grooved or folded nuclei (arrows) suggestive of Langerhans cell differentiation (B, hematoxylin and eosin; original magnification × 400). Reactivity with CD68, a histiocyte-associated marker, is demonstrated in the neoplastic cells (B, KP1 [anti-CD68]).
tissue samples was established by reaction with a poly-dT probe.

**Gene rearrangement studies.** A clonal rearrangement of the T-cell receptor beta-chain gene was found in the THL of patient no. 1; there was no rearrangement of the immunoglobulin heavy-chain gene or light-chain genes.

**DISCUSSION**

We report three cases of THL that arose after therapy for Lyl or ALL. These tumors expressed histiocytic markers and lacked B-cell and T-cell lineage-specific markers, evidence against B- or T-lineage lymphoma. During the years 1975 to 1981, several investigators reported histiocytic neoplasms in association with ALL, which were not studied by immunophenotyping and appear to represent a variety of entities containing histiocytes (discussed further later).

It has been observed for many years that cells with the morphologic appearance of histiocytes are a prominent component in some hematolymphoid malignancies, and, in many instances, these cells appear to be engaged in phagocytosis. However, it has not always been clear whether these cells are, in fact, of histiocytic lineage, or whether they are truly neoplastic (as opposed to proliferating in response to other neoplastic cells or to a viral infection). Nonetheless, before the application of immunophenotyping, there were reports of histiocytic neoplasms; these reports used a variety of names, most commonly malignant histiocytosis. The application of immunohistochemical staining has shown that, in some cases, histiocytes in the tumor, while numerous and sometimes hemophagocytic, do not stain for these markers and have benign or reactive cytologic features. When immunostaining is applied, some older cases of malignant histiocytosis may also correspond to other newer categories of non-Hodgkin's lymphomas of B, T, or null lineage, in which histiocytes are a prominent, but reactive component. In such cases, immunostains for markers of lymphoid lineages highlight a minor population of cells with malignant cytologic features, and these cells may also show phenotypic aberrancies such as expression of CD15, CD30, or epithelial membrane antigen; histiocytes in the tumor, while numerous and sometimes hemophagocytic, do not stain for these markers and have benign or reactive cytologic features. When immunostaining is applied, some older cases of malignant histiocytosis may also correspond to other newer categories of non-Hodgkin's lymphomas with prominent reactive histiocytes, such as histiocytic-rich B-cell lymphoma. Still other cases of malignant histiocytosis may be diagnosed as non-neoplastic conditions in which histiocytes are prominent, most notably, hemophagocytic syndromes.

Without the benefit of immunophenotyping, therefore, it is difficult to determine the nature of the histiocyte neoplasms in the earlier reports of histiocytic neoplasms in association with ALL. Each of these reports describes prominent erythrophagocytosis in atypical histiocytes, a phenomenon that is more prominent in reactive histiocytes than in malignant histiocytes. At least some of these reports describe and illustrate cytologic features of malignancy, but it is not clear whether these represent a minority neoplastic cell population associated with reactive histiocytes. Other studies do not describe or illustrate cytologic features indicative of malignancy, raising the possibility of a histiocytic proliferation reactive to a viral infection.

In making the diagnosis of THL, it is important to exclude virus-associated histiocytic proliferations. EBV has been strongly associated with hemophagocytic histiocytic proliferations; in situ staining detected EBV EBER-1 RNA in one reported case, and EBV-associated hemophagocytic syndromes have been reported following chemotherapy for ALL. The histologic features in our cases were not those of a virus-associated hemophagocytic syndrome, and none of our cases contained EBV EBER-1 RNA by in situ hybridization studies. There was no other known evidence of viral infection in our three cases, and tissue culture and serology from patient no. 2 were negative for herpes simplex virus and cytomegalovirus. Furthermore, hemophagocytic histiocytic proliferations (and many cases of ALCL, previously diagnosed as malignant histiocytosis) usually exhibit fulminant systemic clinical phenomena, including fever and profound cytopenia; these were absent in our three cases of THL. However, there is precedent in the literature for a relationship between ALL and histiocytic proliferations, both reactive hemophagocytic syndromes and Langerhans cell histiocytosis. McClain et al reviewed the occurrence of virus-associated histiocytic proliferations in children. Yin et al reported a case of a viral histiocytic medullary reticulosis-like syndrome caused by parainfluenza virus, their patient received supportive care and recovered completely. However, some cases of histiocytic proliferations occurring after therapy for ALL have been lethal, whether idiopathic or due to known viruses such as CMV.

The definition of true histiocytic neoplasms has changed over the past 20 years, mostly due to advances in immunophenotyping. A number of earlier studies examined various histiocytic markers in normal and malignant cells of presumed histiocytic lineage, with mixed results, particularly regarding the nature of malignant histiocytosis. However, there is currently a general consensus that THLs should express at least some of the enzymes or surface antigens that have been found to be specific for histiocytes, and lack reactivity for specific markers of other lineages; with this restricted definition, THLs have been reported but are rare tumors, distinct from other large-cell lymphomas. Only a limited number of markers of histiocytic differentiation are applicable to paraffin sections, and these are not entirely specific; the KP1 antibody to CD68, the chief marker that we used for this purpose, stains a small proportion of B-lineage large-cell lymphomas. CD68 was expressed by all of our THLs, but their failure to express B- or T-lineage markers, along with the morphologic features, was equally compelling evidence of histiocytic lineage. Their failure to express CD30 also argues against a diagnosis of ALCL, in keeping with their morphology, although CD30 is expressed by a subset of histiocytic neoplasms.

At least some investigators suggest that the presence of a clonal TCR-beta gene rearrangement, which we found in the THL of case no. 1, should exclude the diagnosis of a true histiocytic neoplasm. However, while TCR-beta and immunoglobulin gene rearrangements usually demonstrate lin-
TRUE HISTIOCYTIC LYMPHOMAS

eage and clonality of T-cell and B-cell neoplasms, respectively, it has been well demonstrated that gene rearrangements are not always lineage-specific,11,12,55-55 In particular, there are several reports and series of histiocytic neoplasms in which immunoglobulin and/or TCR-beta genes have been clonally rearranged.5,49,56,57

Most cases of THL have arisen without another prior neoplasm or therapy, and to our knowledge the report of van der Kwast et al is the only one which documents fully a true histiocytic phenotype in a malignant proliferation associated with ALL.14 In that report, the investigators described the occurrence of a true histiocytic neoplasm with one rearranged IgH gene and a t(10;11) in the setting of a T-lymphoblastic lymphoma (not genotyped at original diagnosis); they concluded that the histiocytic neoplasm was present at the time of initial presentation with T-LyL, and that the two neoplasms were morphologically and immunophenotypically distinct.

The second neoplasms in our three cases were all clinically and morphologically malignant, and displayed convincing morphologic and immunophenotypic evidence of histiocytic differentiation. The question arises whether these THLs were related to the original lymphoblastic neoplasms in these patients, or were unrelated neoplasms that arose secondary to the therapy for lymphoblastic disease. Because THLs are rare, their secondary occurrence in three patients with lymphoblastic neoplasms seems greater than would be predicted by chance alone; however, this remains an exceedingly rare phenomenon, and its true incidence cannot be estimated from our practice, since these cases were referred in consultation because of the secondary neoplasms. If there is a causal relationship between the primary lymphoblastic neoplasms and the THLs, one possibility may be the therapy for the LyL or ALL, since secondary hematolymphoid neoplasms are a known complication of many antineoplastic regimens. However, these three patients received different regimens for their LyL or ALL, none of which included VP-16, which has a high rate of inducing acute myeloid leukemia.18 In addition, with the possible exception of VP-16, therapy-related neoplasms usually require a longer interval for their development than the 10- to 20-month span in these cases. Another possible mechanism of causation is that the second neoplasms arose in a posttreatment state of immunodeficiency, as occurs in several immunodeficiency states (human immunodeficiency virus [HIV]-related, or immunosuppression for organ transplants or collagen-vascular disease); however, such second neoplasms usually show the presence of EBV by in situ hybridization for EBER-1 RNA, and we are not aware of any such cases of true histiocytic lineage. A third possibility for a causal relationship in these cases is that the THLs may represent transformation of the original LyL or ALL.

Hematologists, oncologists, and pathologists will benefit from the knowledge that THLs, documented using current techniques, may occur following otherwise successful treatment of lymphoblastic neoplasms. These are morphologically and immunophenotypically distinct from the lymphoblastic neoplasms and appear to display an aggressive clinical behavior. Additional studies of such cases will be needed to provide information on the possible mechanism of this phenomenon.

REFERENCES

True histiocytic lymphoma following therapy for lymphoblastic neoplasms

RA Soslow, RE Davis, RA Warnke, ML Cleary and OW Kamel